Last year nabumetone (Relifex - Bencard) was introduced for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA). It is a non-steroidal anti-inflammatory drug (NSAID) which, like several other NSAIDs, is claimed to have the advantage over other NSAIDs of a lower risk of gastric mucosal irritation. Does the clinical evidence support this claim?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.